Janus Henderson Group PLC Sells 1,660,724 Shares of Enliven Therapeutics, Inc. $ELVN

Posted by George Bondi on Aug 11th, 2026

Janus Henderson Group PLC lowered its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 99.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,000 shares of the company’s stock after selling 1,660,724 shares during the quarter. Janus Henderson Group PLC’s holdings in Enliven Therapeutics were worth $431,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vestal Point Capital LP increased its holdings in Enliven Therapeutics by 230.2% in the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after buying an additional 2,670,000 shares in the last quarter. Siren L.L.C. purchased a new position in Enliven Therapeutics in the 1st quarter worth about $29,252,000. Affinity Asset Advisors LLC bought a new position in Enliven Therapeutics during the 1st quarter valued at about $23,007,000. TCG Crossover Management LLC bought a new stake in shares of Enliven Therapeutics in the second quarter worth approximately $9,990,000. Finally, Duquesne Family Office LLC grew its stake in shares of Enliven Therapeutics by 104.6% in the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after acquiring an additional 484,405 shares during the period. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $59.42 on Tuesday. Enliven Therapeutics, Inc. has a 1-year low of $14.78 and a 1-year high of $62.32. The company has a market capitalization of $4.35 billion, a P/E ratio of -35.58 and a beta of 0.27. The firm’s 50 day simple moving average is $49.06 and its two-hundred day simple moving average is $40.00.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction dated Friday, July 17th. The stock was sold at an average price of $52.64, for a total transaction of $316,787.52. Following the sale, the chief financial officer directly owned 46,054 shares of the company’s stock, valued at $2,424,282.56. This trade represents a 11.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $34.54, for a total value of $345,400.00. Following the sale, the director directly owned 51,884 shares in the company, valued at approximately $1,792,073.36. This represents a 16.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 190,831 shares of company stock valued at $10,991,723. Company insiders own 3.00% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Mizuho boosted their price objective on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Guggenheim cut their target price on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Thursday. JonesTrading boosted their target price on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, The Goldman Sachs Group increased their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $72.67.

Check Out Our Latest Analysis on Enliven Therapeutics

Enliven Therapeutics Profile

(Free Report)

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.